The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

CellCentric to Participate in Upcoming Investor Conferences

By: Newsfile

Cambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - August 5, 2025) -  CellCentric, a privately held biotechnology company developing inobrodib, a first-in-class p300/CBP inhibitor for multiple myeloma, today announced that members of its senior management team will participate in several upcoming investor conferences.

These events provide an opportunity to engage with the investment community and highlight the company's clinical progress with inobrodib, which will be entering a potentially registration enabling study later this year.

Upcoming appearances include:

  • Oppenheimer & Co.'s 2025 Biotech in the Berkshires, Berkshires, MA
    Presentation time: Tuesday, August 5, 2025, 11:51am ET
  • Citi's 2025 Biopharma Back to School Conference, Boston, MA
    1x1s only: Tuesday, September 2, 2025
  • 2025 Wells Fargo Healthcare Conference, Boston, MA
    Presentation time: September 3, 10:15am ET
  • Cantor Global Healthcare Conference, New York, NY
    1x1s only: September 4, 2025
  • Morgan Stanley Health Care Conference, New York, NY
    Presentation time: September 8, 2025, 3:20pm ET
  • BofA Securities Healthcare Trailblazers Private Company Conference, Boston, MA
    1x1s only: September 17, 2025

For more information or to request a meeting, please contact: IR@cellcentric.com

About inobrodib

Inobrodib is a potential new treatment for people with cancer, and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, including MYC and IRF4. It has been evaluated in over 400 patients to date and has a favourable safety and tolerability profile. Clinical activity has been seen in multiple settings, both solid tumour and hematologic malignancies. Delivered as an oral capsule, it is easy for patients to take and can be used at home without the need for intensive monitoring. Its differentiated profile may broaden use among patients who cannot tolerate or access other treatments, while its ease of administration could reduce healthcare system burden relative to more complex therapies.

About CellCentric
CellCentric is a privately held biotechnology company advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor. Inobrodib is in a Phase II clinical trial for patients with relapsed/refractory multiple myeloma, with additional indications under consideration. CellCentric is supported by a robust IP portfolio and external validation through clinical collaborations and strategic partnerships. Headquartered in the UK with expanding U.S. operations, CellCentric is backed by a global syndicate of life science investors, including RA Capital, Forbion (including ForCal), Morningside, Pfizer Ventures, Avego, and the American Cancer Society's BrightEdge Fund. For more information, please visit: www.cellcentric.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261279

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.